Stool testing for the early detection of pancreatic cancer: rationale and current evidence

Haug, Ulrike; Wente, Moritz N.; Seiler, Christoph M.; Jesnowski, Ralf; Brenner, Hermann

doi:10.1586/14737159.8.6.753

Cited by 26 publications

(16 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mutation rate of the K-ras gene in pancreatic cancer was 81.8%, which is higher than that reported by previous studies (24,25). Fecal DNA from pancreatic cancer patients had a higher mutation rate than that of patients with pancreatic benign diseases and healthy controls (P<0.05).…”

Section: Discussioncontrasting

confidence: 61%

Detection of K‑ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study

Wang

Chen

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the feasibility and effectiveness of detecting K-ras mutation by using magnetic nanoparticles in fecal samples of patients with pancreatic cancer at different stages. The novel methodology of K-ras mutation detection was compared to the existing methodology of cancer antigen (CA)19-9 examination. Patients with pancreatic cancer (n=88), pancreatic benign diseases who displayed chronic pancreatitis (n=35), pancreatic mucinous cyst neoplasms (n=10) and pancreatic serous cyst (n=9) admitted to the Department of Surgery, Jiaxing Second Hospital were enrolled in the present study. Fecal samples were collected from all patients, DNA was extracted and magnetic nanoprobe was then used to detect K-ras mutation. The results obtained using the novel magnetic nanoprobe detection technique showed a K-ras mutation rate of 81.8% (72/88) in the patients with pancreatic cancer and 18.5% (10/54) in patients with pancreatic benign diseases. In patients with pancreatic cancer, the K-ras mutation rate was comparable in stages I + IIA and IIB + III + IV (78.9 vs. 84.0%; P>0.05). The sensitivity and specificity of K-ras mutation for detection of pancreatic cancer was 81.8 and 81.5%, respectively. Sixty-eight pancreatic cancer patients had >37 U/ml CA99 with a sensitivity and specificity for pancreatic cancer detection of 77.3 and 77.8%, which was not significantly lower than detection by the fecal K-ras mutations (P>0.05). Combinational detection of fecal K-ras mutations and serum CA19-9 significantly increased the sensitivity regarding pancreatic cancer detection to 97.7% (P<0.05), while the specificity was not enhanced (80.9%; P>0.05) compared with fecal K-ras mutations or CA19-9 alone. The findings showed that the magnetic nanoprobe is able to detect fecal K-ras mutations in different stages of pancreatic cancer, with comparable sensitivity and specificity to CA19-9 examination for differentiating pancreatic cancer. Furthermore, combined detection of CA19-9 and K-ras mutations has enhanced sensitivity compared with CA19-9 alone.

show abstract

Section: Discussioncontrasting

confidence: 61%

Detection of K‑ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study

Wang

Chen

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…It was shown, that it is useful as well to collect blood samples before treatment and to combine blood tests with others (31). Also, the testing for the presence of mutant KRAS in stool has been proposed for the detection of pancreatic and colorectal carcinoma (32,33). Some studies mentioned other samples like bile or pancreatic juice (34,13,29).…”

Section: Discussionmentioning

confidence: 99%

Detection of point mutations in KRAS oncogene by real-time PCR-based genotyping assay in GIT diseases

Ugorcakova

Hlavatý²,

Novotna³

et al. 2012

BLL

View full text Add to dashboard Cite

Abstract:Objectives: The determination of gene mutations is important for the diagnosis and prognosis of various gastrointestinal cancers. The aim of our study was to develop a new procedure for the analysis of KRAS gene mutation by application of the real-time PCR method. Background: The detection process requires discriminate trace amount of mutant allele in a large excess of wild-type DNA in various samples. Methods:The real-time PCR based technique using hybridization probes for fi ve most frequently KRAS codon 12 mutations and WT specifi c peptide nucleic acid (PNA) was performed. Our multiplex detection system was tested in various DNA samples (tissue, bile, pancreatic juice) of patients with different diagnoses of gastrointestinal tract disease obtained by endoscopy and ERCP. Results: We designed and optimized the real-time PCR conditions and tested various amount of PNA in PCR reaction to suppress amplifi cation of the wild-type DNA. We determined the interassay variability of the melting temperatures and the results of mutation testing were confi rmed by DNA sequencing with the 100 % accuracy. Incidence of searched mutations was 67.5 % in cohort of 40 patients; for KRAS G12D it was in 44.4 %, KRAS G12V in 22.2 %, KRAS G12S in 14.8 %, KRAS G12A in 14.8 % and KRAS G12C in 3.8 %. The sensitivity of the assays is 1x10 -5 . Conclusions: Advantages of this technique are rapidity, accuracy and it is generally easy to perform. This method can be adapted for synchronic detection of multiple mutations and after readjustment by other type mutation of KRAS gene may serve as useful clinical tool for analyzing point mutations in various clinical samples (Tab. 3, Fig. 3, Ref. 42). Full Text in PDF www.elis.sk.

show abstract

“…For example, DNA containing mutations in TP53 can be found in the serum of colorectal and liver cancer patients, 71,72 stool of colorectal and pancreatic cancer patients, 73,74 urine of bladder cancer patients, 75,76 saliva of head and neck squamous cell carcinoma patients, 77 sputum of lung cancer patients, 78 and more. In many of the cases studied, the mutations found in the body fluid DNA were identical to the ones found in the primary tumor tissue of the patient, thus confirming their tumoral origin.…”

Section: P53-specific Antibodies and Free Circulating Dna As Biomarkementioning

confidence: 99%

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin

Brosh²,

Oren³

et al. 2011

Genes & Cancer

833

586

View full text Add to dashboard Cite

Inactivation of the p53 tumor suppressor is a frequent event in tumorigenesis. In most cases, the p53 gene is mutated, giving rise to a stable mutant protein whose accumulation is regarded as a hallmark of cancer cells. Mutant p53 proteins not only lose their tumor suppressive activities but often gain additional oncogenic functions that endow cells with growth and survival advantages. Interestingly, mutations in the p53 gene were shown to occur at different phases of the multistep process of malignant transformation, thus contributing differentially to tumor initiation, promotion, aggressiveness, and metastasis. Here, the authors review the different studies on the involvement of p53 inactivation at various stages of tumorigenesis and highlight the specific contribution of p53 mutations at each phase of cancer progression.

show abstract

Stool testing for the early detection of pancreatic cancer: rationale and current evidence

Cited by 26 publications

References 49 publications

Detection of K‑ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study

Detection of K‑ras gene mutations in feces by magnetic nanoprobe in patients with pancreatic cancer: A preliminary study

Detection of point mutations in KRAS oncogene by real-time PCR-based genotyping assay in GIT diseases

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Contact Info

Product

Resources

About